Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder
By Christoph U. Correll, Richard C. Josiassen, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
By Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
By John M. Kane, Christoph U. Correll, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects
By Rosa Luo, Haig Bozigian, Roland Jimenez, Gordon Loewen, Christopher F. O’Brien
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil
By Henry A. Nasrallah, Ralph Aquila, Arielle D. Stanford, Hasan H. Jamal, Peter J. Weiden, Robert Risinger
A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil
By Robert Risinger, Marjie Hard, Peter J. Weiden
Geriatric Depression Scale (Short Form)
Novel Mechanisms in the Future of Cancer Treatment: Angiogenesis & Signal Transduction
MODERATOR: Michael Goldstein, MD
DISCUSSANTS: Roy S. Herbst, MD, PhD, and Michael S. Gordon, MD
Managing Deep Vein Thrombosis Risk in Oncology Patients Office and Outpatient Settings
MODERATOR: Brian A. Meltzer, MD, MBA
DISCUSSANTS: Leo R. Zacharski, MS, MD, and Steven R. Deitcher, MD
Teaching Monograph Grand Round Series
Quality-of-Life and Pharmacoeconomic Considerations of Obsessive-Compulsive Disorder
Moderator: Eric Hollander, MD
Discussants: Myrna Weissman, PhD, and Lorrin Koran, MD
Critical Analysis of Recent Phase III Studies for the Treatment of Colorectal Cancer Implications for Future Clinical Trial Design
DISCUSSANTS: John S. Macdonald, MD, Richard Goldberg MD, Leonard B. Saltz, MD, Daniel G. Haller, MD,
and Richard Simon, DSc
A Discussion on the Methodologies Used to Evaluate Antidepressants
MODERATOR: Jan A. Fawcett, MD
DISCUSSANTS: Norman Sussman, MD Jeffrey H. Newcorn, MD
La guía 2016 sobre interacciones entre medicamentos psicotrópicos, Part 2
C. Lindsay DeVane, PharmD y Charles B. Nemeroff, MD, PhD